Home LiteratureArticle Details
PMID: 17504213 Published · ppublish English Journal Article Review

Interferon: cellular executioner or white knight?

Current medicinal chemistry ·Vol. 14 ·No. 12 ·2007-00-00 ·Pages 1279-89

Maher SG, Romero-Weaver AL, Scarzello AJ, Gamero AM

Abstract

Interferons (IFNs) are a family of pleiotropic cytokines that typically exhibit antiviral, antiproliferative, antitumor, and immunomodulatory properties. While their complex mechanisms of action remain unclear, IFNs are used clinically in the treatment of viral infections, such as hepatitis B and hepatitis C, and remain the primary treatment for a limited number of malignancies, such as melanoma, hairy cell leukemia, and non-Hodgkin's lymphoma and in autoimmune diseases such as multiple sclerosis. IFNs not only regulate somatic cell growth and division but also influence cell survival through the modulation of apoptosis. Paradoxically, IFNs are described to be both pro- and anti-apoptotic in nature. The biological effects of IFNs are primarily mediated via activation of the JAK/STAT pathway, formation of the ISGF3 and STAT1:STAT1 protein complexes, and the subsequent induction of IFN-stimulated genes. However, the activation of JAK/STAT-independent signal transduction pathways also contribute to IFN-mediated responses. To further demonstrate the complexity of the downstream events following stimulation, oligonucleotide microarray studies have shown that in excess of 300 genes are induced following treatment with IFN, some of which are crucial to the induction of apoptosis and cell growth control. In this review we describe the recent advances made in elucidating the various signaling pathways that are activated by IFNs and how these diverse signals contribute to the regulation of cell growth and apoptosis and inhibition of viral replication. Furthermore, we highlight the role of specific signaling molecules and the function(s) of particular IFN-stimulated genes that have been implicated in determining cell fate in response to IFN, as well as the clinical experience of IFN immunotherapy.

MeSH Terms
Antibody Formation/drug effects,physiology Apoptosis/drug effects Cell Proliferation/drug effects Cytokines/physiology Humans Immunity, Cellular/drug effects,physiology Immunologic Factors/physiology Insulin Receptor Substrate Proteins Interferon Type I/physiology Interferon-gamma/physiology Interferons/adverse effects,immunology,physiology,therapeutic use Interleukins/physiology Janus Kinases/physiology Phosphoproteins/physiology Proto-Oncogene Proteins c-crk/physiology Receptor, Insulin/physiology STAT Transcription Factors/physiology Signal Transduction/physiology Virus Diseases/drug therapy p38 Mitogen-Activated Protein Kinases/physiology
Chemicals
Cytokines IFNL1 protein, human IRS1 protein, human Immunologic Factors Insulin Receptor Substrate Proteins Interferon Type I Interleukins Phosphoproteins Proto-Oncogene Proteins c-crk STAT Transcription Factors Interferon-gamma Interferons Receptor, Insulin Janus Kinases p38 Mitogen-Activated Protein Kinases
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Maher S G
Cancer and Inflammation Program, Laboratory of Experimental Immunology, National Cancer Institute, National Institutes of Health, Frederick, MD 21702-1201, USA.
Romero-Weaver A L
Scarzello A J
Gamero A M
Article Info
Journal
Current medicinal chemistry
Abbr.
Curr Med Chem
ISSN
0929-8673
Published
2007-00-00
Pages
1279-89
Language
English
Region
United Arab Emirates
NLM ID
9440157
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com